Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel ...
Building on its international presence in the oncology space, Venus Remedies, a global leader in pharmaceutical innovation, has secured marketing authorisation for docetaxel from Israel and cytarabine from Colombia.
TAIPEI, Taiwan and SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that...
First study of patients with metastatic prostate cancer to evaluate standard-of-care chemotherapy (docetaxel) combined with an antibody drug conjugate (PDS0301).Decrease in prostate specific antigen...
The novel HER2-targeted bispecific antibody zanidatamab (ZW25) in combination with docetaxel demonstrated efficacy with a manageable safety profile as first-line treatment in patients with advanced HER2-positive breast cancer, according to updated data from a phase 1b/2 study (NCT04276493) presented at the 2023 ASCO Breakthrough Meeting.
FLORHAM PARK, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
Intas Pharmaceuticals Limited on FDA Import Alert List
Pharma major Venus Remedies Ltd on Thursday said it has secured marketing authorisation from Saudi Arabia for Docetaxel -- a widely used chemotherapy drug. The development comes three months after the company received good manufacturing practices (GMP) certification from the Saudi Food and Drug Authority (SFDA) for all its production facilities at its unit in Baddi, Himachal Pradesh.nnnRead more at:nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/venus-remedies-gets-marketing-authorization-from-saudi-arabia-for-chemotherapy-drug-docetaxel/articleshow/100669448.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Mylan's Generic Docetaxel Receives Receives Approval in the U.S.
The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide is already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease.